Vast molecular profiling and clinical data effort is designed to support data-driven discovery of new therapies while providing participants with valuable information to improve patient care
CAMBRIDGE, MA — October 15, 2015 — Genospace, a precision medicine software company that has developed a comprehensive suite of tools enabling the broad use of genomic and other biomedical data in research and clinical care, today announced that Sequence Bioinformatics, Inc. and the Government of Newfoundland and Labrador have selected Genospace Population Analytics™ to support a groundbreaking precision medicine initiative.
Sequence Bio, in partnership with the Government of Newfoundland and Labrador, seeks to engage 100,000 consenting participants in a large-scale initiative to capture a wealth of genomic and phenotypic data. The initiative will make the resulting information and analysis available to a variety of organizations in order to improve patient care.
“The Newfoundland and Labrador population is a unique resource for genetic investigation of complex diseases,” said Mick Correll, co-founder and chief executive officer of Genospace. “The province’s collaboration with Sequence Bio takes a community-based approach to apply the latest genomic technologies to advance data-driven precision medicine. We are excited to power this important initiative.”
Genospace was selected by Sequence Bio to provide a comprehensive software platform to power the initiative. The company’s secure infrastructure for managing genomic and phenotypic information provides a foundation upon which Genospace Population Analytics enables collaboration between academic, government and industry partners. The platform also provides valuable translational medicine capabilities that will directly impact patient care.
“We selected Genospace for its experience deploying interactive and accessible solutions for customers in research and clinical care. As a company at the forefront of precision medicine, we required a partner that can provide advanced analytical capabilities in a platform that is interactive and accessible to a variety of stakeholders. Genospace enables our collaborators to efficiently gain insight from large quantities of complex information,” said Tyler Wish, co-founder and chief executive officer of Sequence Bio.
About Sequence Bioinformatics
Located in Newfoundland and Labrador, Sequence Bio is a privately held company leading a large-scale precision medicine initiative that will transform patient outcomes and care in the province. Sequence Bio is developing a data and analysis platform that integrates high-quality, real-world data with modern analytics. Our approach is based on partnership and innovation focused on improving the lives of patients and families. Visit www.sequencebio.co for more information.
At Genospace, we are Digital Architects of Genomic Medicine™. Genospace has built a comprehensive platform for precision medicine to enable interpretation, analysis, reporting and collaboration on high-dimensional genomic and other biomedical data. With specific applications supporting research, development, pathology and clinical care, many of the most advanced precision medicine organizations are powered by Genospace. Visit www.genospace.com for more information.